Three programs. One quantum-enhanced platform. Eight to sixteen weeks from sequence to in-vitro PoC†; in-vivo timeline partner-lab dependent.
● Live in your browser — real ESMFold + Mol*, no login, no signup.
† Design targets and in-silico / modeled figures — not yet demonstrated in vivo. Library size is current. Measured results publish on Benchmarks as programs mature.
Quantum-enhanced AI fused with a wet-lab data flywheel. Each layer feeds the next; each candidate carries a cryptographically anchored evidence trail.
Patent-defensible multi-specifics across oncology, neurology and senolytics — each on the same eight-to-sixteen-week path from sequence to in-vitro PoC; in-vivo schedule partner-lab dependent.
Gastric / GEJ adenocarcinoma. Tumor-restricted T-cell engagement with 4-1BB costimulation to address CD3-bispecific exhaustion. Provisional filed Q2 '26.
Blood-brain-barrier penetration shuttle for CNS-restricted biologics. Bispecific VHH design optimized for transcytosis kinetics over receptor sequestration.
Carbohydrate-binding active space — the flagship moat. Senescence-cell targeting via GD3 ganglioside (Iltis et al., Nat Aging 2024). Second arm provides survival-pathway gating; specific co-target under wet-lab evaluation.
On raw folding accuracy, AlphaFold 3 and Chai-2 set the bar; NOVA-3 wraps them. Our differentiation is upstream — multi-specific composability via the Module Library — and downstream — quantum-corrected refinement, cryptographic provenance, and a wet-lab flywheel. Every result is reproducible from an Evidence Bundle.
Curated, schema-typed Module Library across binders / linkers / hinges / effectors. None of AF3, Chai-2, Boltz-2 or ESM-3 ships an equivalent. We compose; they predict.
CVaR-VQE on IBM Heron r3 for carbohydrate / glycan active spaces. No claim of demonstrated quantum advantage in ground-state chemistry — we engage with the open question.
No surveyed competitor in the AI/quantum drug-discovery set has shipped OpenTimestamps-anchored Evidence Bundles. Pharma diligence gets notary-grade invention dates.
QAI Labs Ltd. is a Delaware corporation headquartered in Sugar Land, Texas, building at the intersection of pharma business development, quantum hardware partnerships, and multi-specific antibody engineering — with collaborators across North America, Europe, and Asia-Pacific.
Former Medarex / Bristol-Myers Squibb. Led antibody engineering on three programs to Phase I/II. At QAI Labs, oversees company operations, the NOVA-3 platform, and US-facing partnerships including the IBM Quantum and Quantinuum integrations.
Serial entrepreneur and clinical physician with deep multi-specific antibody design experience. Co-founded QAI Labs and leads platform development across the NOVA-3 module library, the design pipeline, and the three internal P1 / P2 / P3 programs.
Inventor of the proprietary XFab platform for molecular simulation. Owns the quantum-augmented design layer of NOVA-3 — CVaR-VQE active-space corrections, QAOA assignment optimization, and the hardware-software interface to IBM Quantum and Quantinuum.
Pharma BD, partner labs, and quantum hardware collaborations. The first conversation usually starts with a P3 walkthrough and an Evidence Bundle review. Or submit a target antigen below and we'll scope a design in 48 hours.